Comparison of common side effects from mood stabilizers and antipsychotics between pediatric and adult patients with bipolar disorder: a systematic review of randomized, double-blind, placebo-controlled trials

References

• Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005 Mar;44(3):213–235. PubMed PMID: 15725966.
   PubMed Web of Science ®Google Scholar
• Pfeifer JC, Kowatch RA, DelBello MP. The use of antipsychotics in children and adolescents with bipolar disorders. Expert Opin Pharmacother. 2007 Nov;8(16):2673–2687. PubMed PMID: 17956191. DOI:10.1517/14656566.8.16.2673.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018 Mar;20(2):97–170. PubMed PMID: 29536616; PubMed Central PMCID: PMCPMC5947163.
   PubMed Web of Science ®Google Scholar
• Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2006 Jan;15(1):177–206. PubMed PMID: 16321730. DOI:10.1016/j.chc.2005.08.007
   PubMed Web of Science ®Google Scholar
• Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69 Suppl 4: 26–36. PubMed PMID: 18533766.
   PubMed Web of Science ®Google Scholar
• Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007 Jun;46(6):687–700. PubMed PMID: 17513981. DOI:10.1097/chi.0b013e318040b25f.
   PubMed Web of Science ®Google Scholar
• Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010 Mar;12(2):116–141. PubMed PMID: 20402706. DOI:10.1111/j.1399-5618.2010.00798.x.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009 Aug 18;151(4):W65–94. PubMed PMID: 19622512.
   PubMed Web of Science ®Google Scholar
• Fang F, Sun H, Wang Z, et al. Antipsychotic drug-induced somnolence: incidence, mechanisms, and management. CNS Drugs. 2016 Sep;30(9):845–867. 10.1007/s40263-016-0352-5. PubMed PMID: 27372312.
   PubMed Web of Science ®Google Scholar
• Fang F, Wang Z, Wu R, et al. Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder? Expert Rev Neurother. 2017 Apr;17(4):407–418. PubMed PMID: 28005435. .
   PubMed Web of Science ®Google Scholar
• Gao K, Fang F, Wang Z, et al. Subjective versus objective weight gain during acute treatment with second-generation antipsychotics in schizophrenia and bipolar disorder. J Clin Psychopharmacol. 2016 Dec;36(6):637–642. PubMed PMID: 27753728. DOI:10.1097/JCP.0000000000000596
   PubMed Web of Science ®Google Scholar
• Gao K, Ganocy SJ, Gajwani P, et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry. 2008 Feb;69(2):302–309. PubMed PMID: 18211129.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Elhaj O, Gajwani P, et al. Clinical highlights in bipolar depression: focus on atypical antipsychotics. J Clin Psychiatry. 2005;66 Suppl 5:26–33, PubMed PMID: 16038599
   PubMed Web of Science ®Google Scholar
• Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003 Jul;160(7):1263–1271. PubMed PMID: 12832240. DOI:10.1176/appi.ajp.160.7.1263
   PubMed Web of Science ®Google Scholar
• Findling RL, Robb A, McNamara NK, et al. Lithium in the acute treatment of bipolar I disorder: a double-blind, placebo-controlled study. Pediatrics. 2015 Nov;136(5):885–894. PubMed PMID: 26459650; PubMed Central PMCID: PMCPMC4621794. DOI:10.1542/peds.2015-0743
   PubMed Web of Science ®Google Scholar
• Wagner KD, Redden L, Kowatch RA, et al. A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009 May;48(5):519–532. PubMed PMID: 19325497. DOI:10.1097/CHI.0b013e31819c55ec
   PubMed Web of Science ®Google Scholar
• Wagner KD, Kowatch RA, Emslie GJ, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry. 2006 Jul;163(7):1179–1186. PubMed PMID: 16816222. DOI:10.1176/ajp.2006.163.7.1179
   PubMed Web of Science ®Google Scholar
• Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009 Oct;70(10):1441–1451. PubMed PMID: 19906348. DOI:10.4088/JCP.09m05164yel
   PubMed Web of Science ®Google Scholar
• Findling RL, Landbloom RL, Szegedi A, et al. Asenapine for the acute treatment of pediatric manic or mixed episode of bipolar I disorder. J Am Acad Child Adolesc Psychiatry. 2015 Dec;54(12):1032–1041. PubMed PMID: 26598478. DOI:10.1016/j.jaac.2015.09.007
   PubMed Web of Science ®Google Scholar
• Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007 Oct;164(10):1547–1556. PubMed PMID: 17898346. DOI:10.1176/appi.ajp.2007.06111932
   PubMed Web of Science ®Google Scholar
• Pathak S, Findling RL, Earley WR, et al. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013 Jan;74(1):e100–9. PubMed PMID: 23419231. DOI:10.4088/JCP.11m07424
   PubMed Web of Science ®Google Scholar
• Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009 Nov;11(7):687–700. PubMed PMID: 19839994. DOI:10.1111/j.1399-5618.2009.00750.x
   PubMed Web of Science ®Google Scholar
• Findling RL, Cavus I, Pappadopulos E, et al. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2013 Oct;23(8):545–557. PubMed PMID: 24111980; PubMed Central PMCID: PMCPMC3804078. DOI:10.1089/cap.2012.0029
   PubMed Web of Science ®Google Scholar
• DelBello MP, Goldman R, Phillips D, et al. Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2017 Dec;56(12):1015–1025. PubMed PMID: 29173735. DOI:10.1016/j.jaac.2017.10.006
   PubMed Web of Science ®Google Scholar
• Detke HC, DelBello MP, Landry J, et al. Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2015 Mar;54(3):217–224. PubMed PMID: 25721187. DOI:10.1016/j.jaac.2014.12.012
   PubMed Web of Science ®Google Scholar
• Findling RL, Pathak S, Earley WR, et al. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2014 Aug;24(6):325–335. PubMed PMID: 24956042; PubMed Central PMCID: PMCPMC4137347. DOI:10.1089/cap.2013.0105
   PubMed Web of Science ®Google Scholar
• Keck PE, Orsulak PJ, Cutler AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord. 2009 Jan;112(1–3):36–49. PubMed PMID: 18835043; eng. DOI:10.1016/j.jad.2008.05.014
   PubMed Web of Science ®Google Scholar
• Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005 Jan;66(1):111–121. PubMed PMID: 15669897; eng.
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Bowden CL, Vigna NV, et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania. J Clin Psychiatry. 2010 Apr;71(4):426–432. PubMed PMID: 20361904; eng. DOI:10.4088/JCP.08m04960yel
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Goodwin GM, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry. 2008 Nov;69(11):1776–1789. PubMed PMID: 19014751; eng.
   PubMed Web of Science ®Google Scholar
• Bowden CL, Swann AC, Calabrese JR, et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry. 2006 Oct;67(10):1501–1510. PubMed PMID: 17107240; eng.
   PubMed Web of Science ®Google Scholar
• Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The depakote mania study group. JAMA. 1994 Mar 23–30;271(12):918–924. PubMed PMID: 8120960.
   PubMed Web of Science ®Google Scholar
• Kanba S, Kawasaki H, Ishigooka J, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). World J Biol Psychiatry. 2014 Feb;15(2):113–121. PubMed PMID: 22540407; eng. DOI:10.3109/15622975.2012.669047
   PubMed Web of Science ®Google Scholar
• El Mallakh RS, Vieta E, Rollin L, et al. A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). Eur Neuropsychopharmacol. 2010 Nov;20(11):776–783. PubMed PMID: 20728318; eng. DOI:10.1016/j.euroneuro.2010.07.003
   PubMed Web of Science ®Google Scholar
• Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry. 2009 Jan;194(1):40–48. PubMed PMID: 19118324; eng. DOI:10.1192/bjp.bp.108.049965
   PubMed Web of Science ®Google Scholar
• Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006 Jul;20(4):536–546. PubMed PMID: 16401666; eng. DOI:10.1177/0269881106059693
   PubMed Web of Science ®Google Scholar
• Keck PE Jr., Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003 Sep;160(9):1651–1658. PubMed PMID: 12944341; eng. DOI:10.1176/appi.ajp.160.9.1651
   PubMed Web of Science ®Google Scholar
• Landbloom RL, Mackle M, Wu X, et al. Asenapine: efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder. J Affect Disord. 2016 Jan 15;190:103–110. PubMed PMID: 26496015; eng. DOI:10.1016/j.jad.2015.06.059
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010 Apr;122(1–2):27–38. PubMed PMID: 20096936; eng. DOI:10.1016/j.jad.2009.12.028
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009 Nov;11(7):673–686. PubMed PMID: 19839993; eng. DOI:10.1111/j.1399-5618.2009.00748.x
   PubMed Web of Science ®Google Scholar
• Katagiri H, Takita Y, Tohen M, et al. Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study. J Affect Disord. 2012 Feb;136(3):476–484. PubMed PMID: 22134043; eng. DOI:10.1016/j.jad.2011.10.045
   PubMed Web of Science ®Google Scholar
• Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The olanzipine HGGW study group. Arch Gen Psychiatry. 2000 Sep;57(9):841–849. PubMed PMID: 10986547; eng.
   PubMed Web of Science ®Google Scholar
• Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH study group. Am J Psychiatry. 1999 May;156(5):702–709. PubMed PMID: 10327902; eng. DOI:10.1176/ajp.156.5.702
   PubMed Web of Science ®Google Scholar
• Vieta E, Nuamah IF, Lim P, et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord. 2010 May;12(3):230–243. PubMed PMID: 20565430; eng. DOI:10.1111/j.1399-5618.2010.00815.x
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania–a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 2005 Oct;15(5):573–585. PubMed PMID: 16139175; eng. DOI:10.1016/j.euroneuro.2005.02.006
   PubMed Web of Science ®Google Scholar
• Smulevich AB, Khanna S, Eerdekens M, et al. Acute and continuation risperidone monotherapy in bipolar mania: A 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol [Article]. Eur Neuropsychopharmacol. 2005;15(1):75–84. English. DOI:10.1016/j.euroneuro.2004.06.003
   PubMed Web of Science ®Google Scholar
• Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry. 2005 Sep;187:229–234. PubMed PMID: 16135859; eng. DOI:10.1192/bjp.187.3.229
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Keck PE Jr., Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004 Jun;161(6):1057–1065. PubMed PMID: 15169694; eng. DOI:10.1176/appi.ajp.161.6.1057
   PubMed Web of Science ®Google Scholar
• Vieta E, Ramey T, Keller D, et al. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol. 2010 Apr;24(4):547–558. PubMed PMID: 19074536; eng. DOI:10.1177/0269881108099418
   PubMed Web of Science ®Google Scholar
• Potkin SG, Jr PE K, Segal S, et al. Ziprasidone in acute bipolar mania: A 21-day randomized, double-blind, placebo-controlled replication trial [Article]. J Clin Psychopharmacol. 2005;25(4):301–310. English. DOI:10.1097/01.jcp.0000169068.34322.70
   PubMed Web of Science ®Google Scholar
• Keck PE Jr., Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003 Apr;160(4):741–748. PubMed PMID: 12668364; eng. DOI:10.1176/appi.ajp.160.4.741
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014 Feb;171(2):160–168. PubMed PMID: 24170180; eng. DOI:10.1176/appi.ajp.2013.13070984
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003 Nov;60(11):1079–1088. PubMed PMID: 14609883; eng. DOI:10.1001/archpsyc.60.11.1079
   PubMed Web of Science ®Google Scholar
• Murasaki M, Koyama T, Kanba S, et al. Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression [Article]. Psychopharmacology (Berl). 2018;235(10):2859–2869. English. DOI:10.1007/s00213-018-4977-6
   PubMed Web of Science ®Google Scholar
• Li H, Gu N, Zhang H, et al. Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2016 Apr;233(7):1289–1297. 10.1007/s00213-016-4215-z. PubMed PMID: 26911380; eng.
   PubMed Web of Science ®Google Scholar
• Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010 Feb;121(1–2):106–115. PubMed PMID: 19903574; eng. DOI:10.1016/j.jad.2009.10.007
   PubMed Web of Science ®Google Scholar
• Gao K, Kemp DE, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry. 2011 Aug;72(8):1063–1071. PubMed PMID: 21034695; PubMed Central PMCID: PMCPMC3457049. DOI:10.4088/JCP.09r05535gre
   PubMed Web of Science ®Google Scholar
• De Hert M, Dobbelaere M, Sheridan EM, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011 Apr;26(3):144–158. PubMed PMID: 21295450. DOI:10.1016/j.eurpsy.2010.09.011
   PubMed Web of Science ®Google Scholar
• Andrews PL. Physiology of nausea and vomiting. Br J Anaesth. 1992;69(7 Suppl 1): 2S–19S. PubMed PMID: 1486009.
   PubMed Web of Science ®Google Scholar
• Singh P, Kuo B. Central aspects of nausea and vomiting in GI disorders. Curr Treat Options Gastroenterol. 2016 Dec;14(4):444–451. 10.1007/s11938-016-0107-x. PubMed PMID: 27734216.
   PubMedGoogle Scholar
• Singh P, Yoon SS, Kuo B. Nausea: a review of pathophysiology and therapeutics. Therap Adv Gastroenterol. 2016 Jan;9(1):98–112. 10.1177/1756283X15618131. PubMed PMID: 26770271; PubMed Central PMCID: PMCPMC4699282.
   PubMed Web of Science ®Google Scholar
• Barak N, Beck Y, Albeck JH. Betahistine decreases olanzapine-induced weight gain and somnolence in humans. J Psychopharmacol. 2016 Mar;30(3):237–241. PubMed PMID: 26839321. DOI:10.1177/0269881115626349.
   PubMed Web of Science ®Google Scholar
• Pitzer M. The development of monoaminergic neurotransmitter systems in childhood and adolescence. Int J Dev Neurosci. 2019 Feb 6. PubMed PMID: 30738086. DOI:10.1016/j.ijdevneu.2019.02.002
   PubMed Web of Science ®Google Scholar
• Forcen FE, Radwan K, Arauz A, et al. Drug-induced akathisia in children and adolescents. J Child Adolesc Psychopharmacol. 2017 Feb;27(1):102–103. PubMed PMID: 27405006. DOI:10.1089/cap.2016.0032
   PubMed Web of Science ®Google Scholar
• Kim J, Napadow V, Kuo B, et al. A combined HRV-fMRI approach to assess cortical control of cardiovagal modulation by motion sickness. Conf Proc IEEE Eng Med Biol Soc. 2011;2011:2825–2828. PubMed PMID: 22254929; PubMed Central PMCID: PMCPMC3275420. DOI:10.1109/IEMBS.2011.6090781
   PubMedGoogle Scholar
• Napadow V, Sheehan JD, Kim J, et al. The brain circuitry underlying the temporal evolution of nausea in humans. Cereb Cortex. 2013 Apr;23(4):806–813. PubMed PMID: 22473843; PubMed Central PMCID: PMCPMC3593575. DOI:10.1093/cercor/bhs073
   PubMed Web of Science ®Google Scholar
• Geller B, Luby JL, Joshi P, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry. 2012 May;69(5):515–528. PubMed PMID: 22213771; PubMed Central PMCID: PMCPMC3581342. .
   PubMed Web of Science ®Google Scholar
• Hoertel N, Le Strat Y, Lavaud P, et al. Generalizability of clinical trial results for bipolar disorder to community samples: findings from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry. 2013 Mar;74(3):265–270. PubMed PMID: 23561233. DOI:10.4088/JCP.12m07935
   PubMed Web of Science ®Google Scholar
• Storosum JG, Fouwels A, Gispen-de Wied CC, et al. How real are patients in placebo-controlled studies of acute manic episode? Eur Neuropsychopharmacol. 2004 Aug;14(4):319–323. PubMed PMID: 15163442. DOI:10.1016/j.euroneuro.2003.10.003
   PubMed Web of Science ®Google Scholar
• Zimmerman M, Holst CG, Clark HL, et al. The psychiatric inclusion and exclusion criteria in placebo-controlled monotherapy trials of bipolar depression: an analysis of studies of the past 20 years. CNS Drugs. 2016 Dec;30(12):1209–1218. 10.1007/s40263-016-0381-0. PubMed PMID: 27541608.
   PubMed Web of Science ®Google Scholar
• Fisher AJ, Medaglia JD, Jeronimus BF. Lack of group-to-individual generalizability is a threat to human subjects research. Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):E6106–E6115. PubMed PMID: 29915059; PubMed Central PMCID: PMCPMC6142277. DOI:10.1073/pnas.1711978115.
   PubMed Web of Science ®Google Scholar